Cumulus Oncology
61 Dublin Street, Edinburgh, Midlothian, EH3 6NL, United Kingdom
Overview
Cumulus Oncology develops anti-cancer therapies for clinical settings in areas of high unmet need. We target key pathways to improve the efficacy and outcomes of current and experimental therapies. Cumulus has the backing of a successful entrepreneur in the oncology field and is led by a team of senior professionals and industry partners from across the drug discovery and development sector. Together, we offer a wealth of experience and deep insights into optimum approaches for improved cancer patient outcomes.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 4
Sector focus
- Biotechnology
- Health Care
- Oncology
- Pharmaceutical
Investment portfolio
- Nodus Oncology
Led · Equity · Feb 2023
Nodus Oncology is a biotech company developing molecules that inhibit novel DNA damage response (DDR) targets, including a PARG program acquired from Basilea Pharmaceutica. The company focuses on so-called “third-wave” DDR targets believed to play important roles in the response to DNA damage. Nodus plans to accelerate development of its PARG program in collaboration with Lead Discovery Center GmbH (LDC). It also intends to continue discovery and development of additional novel DDR targets and expand its portfolio. The company is led by CEO Ian Waddell and was founded in September 2022. Nodus recently raised £2.4M to fund these near-term development activities.